How do you approach the "wearing off" phenomenon for patients with multiple sclerosis on B-cell-depleting therapies?  

This is a fairly common, but not universal, phenomenon, and more frequent for patients on ocrelizumab compared to rituximab, ublituximab, and even ofatumumab. I try to make action plans for symptomatic treatment during these periods, e.g., addressing fatigue, pain, and cognitive fog. We can increase...